Atossa Therapeutics, Inc.
ATOS
|
$1.42
3.65%
3.18%
1M
|
Health Technology
(0.0% 1d) (-24.9% 1m) (111.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-15.88% volume)
Earnings Calendar: 2024-03-25
Market Cap: $ 177,931,771
http://www.atossatherapeutics.com
Sec Filling | Patents | 6 employees
(US) Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
breast cancer cancer women diagnostics msa treatment cancer treatments
add to watch list Paper trade email alert is off
Press-releases
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
ATOS | $1.42 3.65% 3.18% 1M
|
Health Technology
|
| O: 0.57%
H: 11.65%
C: 4.55%
disease control treatment trial therapeutics
Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
Published: 2024-03-19 (Crawled : 12:30) - globenewswire.com
ATOS | $1.42 3.65% 3.18% 1M
|
Health Technology
|
| O: 1.55%
H: 19.85%
C: 18.32%
breast update cancer treatment program therapeutics
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
Published: 2024-03-18 (Crawled : 12:30) - globenewswire.com
ATOS | $1.42 3.65% 3.18% 1M
|
Health Technology
|
| O: 0.0%
H: 3.87%
C: 0.0%
nasdaq therapeutics
Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
Published: 2024-03-12 (Crawled : 12:30) - globenewswire.com
ATOS | $1.42 3.65% 3.18% 1M
|
Health Technology
|
| O: 2.5%
H: 8.13%
C: 6.5%
breast cancer specialist therapeutics
Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-03-06 (Crawled : 14:00) - globenewswire.com
ATOS | $1.42 3.65% 3.18% 1M
|
Health Technology
|
| O: 1.96%
H: 15.38%
C: 10.58%
association cancer research meeting trial
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
Published: 2024-02-22 (Crawled : 13:30) - globenewswire.com
ATOS | $1.42 3.65% 3.18% 1M
|
Health Technology
|
| O: 0.0%
H: 3.96%
C: 0.99%
first ongoing therapeutics study
Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial
Published: 2024-02-07 (Crawled : 13:30) - globenewswire.com
ATOS | $1.42 3.65% 3.18% 1M
|
Health Technology
|
| O: 1.66%
H: 4.13%
C: 4.11%
arm trial therapeutics
Atossa Therapeutics Issues Letter to Shareholders
Published: 2024-01-09 (Crawled : 13:30) - globenewswire.com
ATOS | $1.42 3.65% 3.18% 1M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: -4.08%
therapeutics
Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director
Published: 2023-12-04 (Crawled : 13:30) - globenewswire.com
ATOS | $1.42 3.65% 3.18% 1M
|
Health Technology
|
| O: -0.05%
H: 1.4%
C: -3.21%
medical therapeutics
Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial
Published: 2023-11-20 (Crawled : 13:30) - globenewswire.com
ATOS | $1.42 3.65% 3.18% 1M
|
Health Technology
|
| O: -0.34%
H: 9.19%
C: 9.19%
trial therapeutics phase 2
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
| 0000950170-24-031815 | 4 | 2024-03-15 | 2024-03-09 | Buy | A | 20834 | 20834 |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 73% | 27% |
Top 10 Gainers
MTTR | News M | $4.8 175.86% 63.6% 71M
|
AGBA | $2.5 100.0% 56.6% 200M
|
Finance
MLEC | $2.47 76.43% 42.62% 78M
|
n/a
NUWE | $0.334 29.96% 40.99% 2.5M
|
Manufacturing
EDBL | News | $6.26 66.49% 40.13% 16M
|
ATGL | $2.86 46.25% 32.8% 180K
|
VIVK | $1.43 33.65% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.7M
|
SDIG A | $3.64 35.32% 26.0% 990K
|
PROK | $2.72 33.33% 24.58% 2.6M
|
Last 48 Hours Insiders Buying
ETST P 79000 | $0.065 18.18% -67.14% 110K
|
Manufacturing
|
11:30
MCFT P 26039 | $21.5 1.9% 1.86% 110K
|
Consumer Durables
|
00:00
YORW P 29 | $35.42 1.0% 1.02% 66K
|
Utilities
|
19:01
VUZI P 14500 | $1.35 11.57% 10.37% 840K
|
Electronic Technology
|
17:00
BANF P 256 | $91.28 2.24% 2.18% 150K
|
Finance
|
15:30
RMCF | $3.57 0.56% 0.28% 11K
|
Consumer Non-Durables
|
20:10